Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info


P: 781-994-0300 F: 781-376-6019


ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.

Key Statistics


Market Capitalization, $K 426,151
Shares Outstanding, K 108,990
Annual Sales, $ 0 K
Annual Net Income, $ -29,200 K
Last Quarter Sales, $ 4,980 K
Last Quarter Net Income, $ -5,620 K
36-Month Beta 1.63
% of Insider Shareholders 7.90%
% of Institutional Shareholders 65.06%


1-Year Total Return 200.75%
3-Year Total Return 63.93%
5-Year Total Return 76.21%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -116.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 03/05/18
Next Earnings Date 10/31/18
Earnings Per Share ttm -0.16
EPS Growth vs. Prev Qtr -200.00%
EPS Growth vs. Prev Year 44.44%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

ARQL Ratios

Price/Earnings ttm 0.00
Price/Earnings forward -44.10
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -42.71
Return-on-Assets (Before Tax) -22.99
Net Margin % -70.49
Debt/Equity 0.54
Price/Sales 16.32
Price/Cash Flow N/A
Price/Book 4.89
Book Value/Share -0.80
Interest Coverage -18.21
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar